AIM: To observe the treatment of plateau Conbercept age-related macular degeneration(AMD)effect.

METHODS: A total of 70 cases(80 eyes)with plateau AMD were selected from Jan.2014 to Jan.2016 in our hospital. All the patients were randomly divided into observation group of 35 cases(42 eyes)and the control group of 35 cases(38 eyes)respectively. Conbercept and intravitreal triamcinolone injection were done in two groups. The clinical efficacy, the best corrected visual acuity(BCVA), macular central fovea thickness(CRT), intraocular pressure(IOP)and adverse reactions of the two groups were compared.

RESULTS: The total efficiency of treatment in the observation group(95%)was significantly higher than that of control group(79%)(P<0.05). BCVA of 3mo after the treatment, the observation group was significantly higher than that of the control group. CRT, IOP was significantly lower than that of control group(P<0.05). In observation group, the adverse reaction rate of 6%, which was significantly lower than that of the control group of 26%(P<0.05).

CONCLUSION: Conbercept in the treatment of plateau area AMD patients have stable efficacy. It can effectively improve the visual acuity and CRT. The adverse reactions were less.